达维塔保健(DVA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

DVA 达维塔保健

休市中 08-14 16:00:00 EDT

180.06

+0.89

+0.50%

盘后180.06

+0.000.00%

19:34 EDT

最高182.69	最低178.92	成交量50.66万
今开179.00	昨收179.17	日振幅2.10%
总市值115.60亿	流通市值58.75亿	总股本6,420万
成交额9,158万	换手率1.55%	流通股本3,263万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"DVA","market":"US","secType":"STK","nameCN":"达维塔保健","latestPrice":180.06,"timestamp":1786737600000,"preClose":179.17,"halted":0,"volume":506565,"hourTrading":{"tag":"盘后","latestPrice":180.06,"preClose":180.06,"latestTime":"19:34 EDT","volume":41841,"amount":7533878.2397,"timestamp":1786750447887,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.004967349444661578,"floatShares":32629699,"shares":64200000,"eps":12.13,"marketStatus":"休市中","change":0.89,"latestTime":"08-14 16:00:00 EDT","open":179,"high":182.69,"low":178.92,"amount":91579338.32804999,"amplitude":0.021041,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":12.13,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1786953600000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":815029200000,"exchange":"NYSE","adjPreClose":179.17,"preHourTrading":{"tag":"盘前","latestPrice":179,"preClose":179.17,"latestTime":"09:22 EDT","volume":132,"amount":23702.579999999998,"timestamp":1786713750628,"change":-0.17,"changeRate":-0.000949,"amplitude":0.05905},"postHourTrading":{"tag":"盘后","latestPrice":180.06,"preClose":180.06,"latestTime":"19:34 EDT","volume":41841,"amount":7533878.2397,"timestamp":1786750447887,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.5064875073708532,"impliedVol":0.3209,"impliedVolPercentile":0.2271},"requestUrl":"/m/hq/s/DVA/wiki","defaultTab":"wiki","newsList":[{"id":"2658911935","title":"板块普涨之际 十只量化评分强劲的大盘医疗保健股","url":"https://stock-news.laohu8.com/highlight/detail?id=2658911935","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658911935?lang=zh_cn&edition=full","pubTime":"2026-08-11 23:27","pubTimestamp":1786462073,"startTime":"0","endTime":"0","summary":"经历 2022-2023年板块低迷后，医疗保健板块在2026年重新积聚上涨动能。Centene Corporation以4.97分接近满分的量化评分位居榜单首位；Corcept Therapeutics、Bright Spring Health Services紧随其后，评分分别为4.93、4.91；Halozyme Therapeutics、Humana跻身前五，均获强烈“买入”评级。即便板块整体处在历史高位，个股之间量化评分分化依旧显著。","market":"nz","thumbnail":"https://static.szfiu.com/news/20210625/YzM0ZmE0OGYyYmI1ZTk0YjVmZmU4ZTU4MTIzMDA2MDU4MDg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/YzM0ZmE0OGYyYmI1ZTk0YjVmZmU4ZTU4MTIzMDA2MDU4MDg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"303689","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109391861.USD","LU2264538146.SGD","LU1023059063.AUD","LU0097036916.USD","LU2244417387.USD","LU0708995401.HKD","LU0672654240.SGD","SGXZ57979304.SGD","LU1718418525.SGD","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","BK4532","IE0009355771.USD","LU2552382215.SGD","BK4534","UNHG","IE00BJT1NW94.SGD","LU0432979614.USD","LU1983260115.SGD","LU2360032135.SGD","LU2125154778.USD","LU0353189763.USD","LU1037948897.HKD","LU2347655156.SGD","BK4154","LU0211327993.USD","LU1674673428.USD","LU2065169927.USD","LU1084165304.USD","NBIX","IE00B1XK9C88.USD","LU2357305700.SGD","LU1914381329.SGD","LU0011850046.USD","LU0820561818.USD","LU0949170772.SGD","BK4613","SG9999002232.USD","CORT","LU0320765489.SGD","LU1074936037.SGD","LU1989764748.USD","LU2065170008.USD","LU0417517546.SGD","IE00B19Z3581.USD","LU2028103732.USD","LU2211815571.USD","LGHT","LU2362541273.HKD","LU2357627491.SGD","LU2954938101.SGD","LU0648000940.SGD","SG9999014880.SGD","LU1267930573.SGD","BK4198","LU1814569148.SGD","IE00BKVL7J92.USD","LU0980610538.SGD","IE00BJJMRY28.SGD","LU0048584097.USD","FBT","SG9999014906.USD","SG9999001176.USD","HALO","IE00B19Z9P08.USD","LU0795875169.SGD","SG9999014021.USD","SG9999002224.SGD","LU0266013472.USD","BK4139","LU0203347892.USD","IE0004445015.USD","LU0557290698.USD","LU1791710582.SGD","LU1064131342.USD","VEEV","LU0130517989.USD","SG9999013999.USD","LU0354030438.USD","PTH","LU0128525929.USD","LU0289739699.SGD","LU1153585028.USD","BK4533","LU0708994859.HKD","LU0203345920.USD","IE00B4JS1V06.HKD","LU1983299246.USD","LU0316494557.USD","IYH","IE00B894F039.SGD","LU2112291526.USD","LU0109394709.USD","LU1093756325.SGD","UNHW","LU1066051498.USD","LU0211326839.USD","LU0072461881.USD","IE00B19Z8X17.USD","BK4566","LU0211326755.USD","LU0158827781.USD","LU0477156797.USD","LU2462591277.SGD","LU0149725797.USD","RXL","LU2362540622.SGD","LU1732799900.SGD","LU1854103824.USD","TRUH","LU0787776722.HKD","SG9999014898.SGD","LU2236285917.USD","LU0348723411.USD","LU0823416689.USD","IE00BKPKM429.USD","LU2468319806.SGD","LU1670628061.USD","LU0310799852.SGD","LU0965509010.AUD","IE00B7SZLL34.SGD","LU0320765992.SGD","IE0004445239.USD","LU0079474960.USD","LU2361044865.SGD","LU2361044949.HKD","SG9999001176.SGD","LU0965508806.USD","LU1551013342.USD","LU2133065610.SGD","LU0661504455.SGD","CNC","LU0143551892.USD","LU0187121727.USD","IE00BJJMRZ35.SGD","FXH","LU1201861165.SGD","IE00B19Z3B42.SGD","BK4167","SOLV","LU0566484027.USD","LU0861579265.USD","LU1934455863.HKD","IE00BWXC8680.SGD","LU1119994496.HKD","GDOC","LU1267930227.SGD","LU2999663052.SGD","LU1267930730.SGD","LU1069347547.HKD","LU0738911758.USD","MHIP","IE00B7KXQ091.USD","LU1674673691.USD","LU2279689827.SGD","LU1506573853.SGD","IE000M9KFDE8.USD","LU0130102774.USD","LU2242649171.HKD","SG9999017495.SGD","LU0114720955.EUR","LU0154245673.USD","LU1551013425.SGD","LU2089283258.USD","LU1093756168.USD","LU1732800096.USD","LU0029864427.USD","VHT","LU0310800965.SGD","LU1989771016.USD","LU1066051225.USD","LU0648001328.SGD","LU1988902786.USD","LU0342679015.USD","BTSG","LU1559883803.SGD","IE0002141913.USD","UNH","LU1496350502.SGD","LU0058720904.USD","LU1791710400.SGD","SGXZ99366536.SGD","LU1934455277.USD","IE00BFSS7M15.SGD","LU0158827948.USD","IE00BFXG1179.USD","LU1720051017.SGD","LU0545039389.USD","LU0070302665.USD","BK4528","LU0528227936.USD","LU1035773651.USD","IE0005OL40V9.USD","SG9999018857.SGD","LU2089284900.SGD","LU2552382132.HKD","LU0820561909.HKD","LU0912757837.SGD","LU2125154935.USD","LU0052756011.USD","LU0965509283.SGD","LU0689472784.USD","IE00BZ9MQY76.HKD","SG9999014013.SGD","LU2023251221.USD","LU1057294990.SGD","LU0795875086.SGD","LU0238689110.USD","LU0053671581.USD","SGXZ31699556.SGD","IHF","LU1934455194.USD","IE0002270589.USD","LU1261432733.SGD","LU1720051108.HKD","LU2491049909.HKD","LU0683600562.USD","LU2271345857.HKD","PSCH","CNCG","LU0162691827.USD","LU1548497426.USD","LU0130518102.USD","LU2065171311.SGD","LU2362541513.USD","LU0198837287.USD","JDOC","LU0345770308.USD","XLV","BK4581","IE00BSNM7G36.USD","BK4585","LU1003077747.HKD","LU0320765059.SGD","LU0345770993.USD","LU0130103400.USD","IE00B19Z9505.USD","HUM","LU1291159041.SGD","LU2361045086.USD","LU0943347566.SGD","LU2089984988.USD","TMED","LU1670627923.USD","DVA","LU0477156953.USD","IE00B19Z9Z06.USD","LU2324357040.USD","LU1989764664.SGD","IE00BJJMRX11.SGD","SG9999014005.SGD","LU0077335932.USD","LU2491050071.SGD","LU0107464264.USD","LU1201861249.SGD","LU0053666078.USD","FFOX","LU0965509101.SGD","LU2111349929.HKD","IE0034235188.USD","IE00B3T34201.USD","SG9999018865.SGD","IE00BFSS8Q28.SGD","BK4196","BK4559","LU0889565916.HKD","LU0390134368.USD","LU1061106388.HKD","LU1699723380.USD","LU2461242641.AUD","IE00B2B36J28.USD","LU0094547139.USD","LU0553294199.USD","SGXZ81514606.USD","LU1323610961.USD","LU0820562030.AUD","LU0456855351.SGD","IE00B775H168.HKD","IE00BN29S564.USD","IE00B1BXHZ80.USD","BK4504","LU2065171402.SGD","LU0496365809.HKD","LU0251132253.USD","LU0211328371.USD","LU0256863811.USD","LU0310800379.SGD","EKG","IXJ","HRTS","LU2087625088.SGD","LU2491050154.USD","LU0976567544.SGD","SGXZ51526630.SGD","SG9999014914.USD","LU0882574055.USD","LU0354030511.USD","LU0211331839.USD","LU0208291251.USD","LU0122379950.USD","LU1066051811.HKD","BK4007","IE00BZ1G4Q59.USD","LU0128525689.USD","LU1066053197.SGD","LU0234572021.USD","FHLC","LU0859254822.USD","LU1267930490.SGD","IE00B19Z8W00.USD","BK4588","LU1778281490.HKD","LU0353189680.USD","LU0170899867.USD","LU2552382058.USD","LU0154245756.USD","LU1854104046.USD","LU1037948541.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185214762","title":"异动解读｜达维塔保健盘中下跌5.01%，全年指引未上调及伯克希尔减持利空持续发酵","url":"https://stock-news.laohu8.com/highlight/detail?id=1185214762","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1185214762?lang=zh_cn&edition=full","pubTime":"2026-08-07 03:36","pubTimestamp":1786045005,"startTime":"0","endTime":"0","summary":"8月7日，达维塔保健盘中下跌5.01%，报179.23美元/股，成交额1.92亿美元，延续此前跌势。消息面上，公司Q2调整后每股收益4.02美元超预期，但维持全年EPS指引14.10至15.20美元不变，中值14.65美元低于市场预期的14.88美元，被解读为下半年盈利增速放缓信号。同时，SEC文件显示伯克希尔·哈撒韦出售18.3万股公司股票，美银将目标价设定为170美元，低于当前股价，多重利空持续压制股价。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151436346","title":"异动解读｜达维塔保健盘中下跌17.34%，Q2业绩超预期但全年指引未上调叠加伯克希尔减持","url":"https://stock-news.laohu8.com/highlight/detail?id=1151436346","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1151436346?lang=zh_cn&edition=full","pubTime":"2026-08-05 22:34","pubTimestamp":1785940480,"startTime":"0","endTime":"0","summary":"8月5日，达维塔保健盘中下跌17.34%，报188.2美元/股，成交额2.92亿美元。然而公司维持全年调整后每股收益指引14.10至15.20美元不变，指引中值14.65美元低于市场一致预期的14.88美元。由于Q1和Q2连续大幅超预期，市场此前对上调全年指引抱有较高期待，指引维持不变被解读为隐含下半年盈利增速放缓信号。此外，SEC文件显示伯克希尔·哈撒韦近期出售18.3万股达维塔保健股票，美银将目标价调整至170美元，远低于当前股价，多重利空共振加剧抛压。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"达维塔保健盘中下跌17.34%，Q2业绩超预期但全年指引未上调叠加伯克希尔减持","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104962505","title":"异动解读｜达维塔保健盘前下跌5.94%，Q2业绩超预期但全年指引未上调叠加伯克希尔减持","url":"https://stock-news.laohu8.com/highlight/detail?id=1104962505","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1104962505?lang=zh_cn&edition=full","pubTime":"2026-08-05 18:12","pubTimestamp":1785924759,"startTime":"0","endTime":"0","summary":"8月5日，达维塔保健盘前下跌5.94%，报218.0美元/股。然而公司维持全年调整后每股收益指引14.10至15.20美元不变，指引中值14.65美元低于市场一致预期的14.88美元。由于Q1和Q2连续大幅超预期，市场此前对上调全年指引抱有较高期待，指引维持不变被解读为隐含下半年盈利增速放缓信号。此外，SEC文件显示伯克希尔·哈撒韦近期出售18.3万股达维塔保健股票，进一步加剧市场情绪压力。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"达维塔保健盘前下跌5.94%，Q2业绩超预期但全年指引未上调叠加伯克希尔减持","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178423989","title":"异动解读｜达维塔保健夜盘下跌5.83%，Q2业绩超预期但全年指引未上调引发抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=1178423989","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1178423989?lang=zh_cn&edition=full","pubTime":"2026-08-05 09:08","pubTimestamp":1785892114,"startTime":"0","endTime":"0","summary":"8月5日，达维塔保健夜盘下跌5.83%，报214.7美元/股。然而公司维持全年调整后每股收益指引14.10至15.20美元不变，指引中值14.65美元低于市场一致预期的14.88美元。由于Q1和Q2连续大幅超预期，市场此前对上调全年指引抱有较高期待，指引维持不变被解读为隐含下半年盈利增速放缓信号。此外，SEC文件显示伯克希尔·哈撒韦近期出售18.3万股达维塔保健股票，进一步加剧市场情绪压力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197792702","title":"伯克希尔·哈撒韦出售18.298万股达维塔保健股票，平均每股199.55美元，仍持有约2870万股——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1197792702","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197792702?lang=zh_cn&edition=full","pubTime":"2026-08-05 05:41","pubTimestamp":1785879668,"startTime":"0","endTime":"0","summary":"根据美国证券交易委员会（SEC）最新披露的文件显示，伯克希尔·哈撒韦公司已出售了18.298万股达维塔保健（DaVita HealthCare Partners）股票，平均每股售价为199.55美元。此次交易完成后，该公司仍持有约2870万股达维塔保健股份。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4196","BK4559","DVA","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165475817","title":"异动解读 | 达维塔保健盘后大跌6.77%，Q2业绩超预期但全年指引未上调引发市场抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=1165475817","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165475817?lang=zh_cn&edition=full","pubTime":"2026-08-05 04:42","pubTimestamp":1785876138,"startTime":"0","endTime":"0","summary":"达维塔保健（DVA）今日盘后股价大跌6.77%，引发市场广泛关注。消息面上，公司发布了第二季度财报，调整后每股收益为4.02美元，超出市场预期的3.88美元，同比增长36.27%；营收35.54亿美元，同样高于预期的34.96亿美元。尽管业绩表现强劲，但公司维持全年调整后每股收益指引14.10至15.20美元不变，指引中值14.65美元低于市场一致预期的14.88美元。由于达维塔保健在第一季度和第二季度连续大幅超越预期，市场原本对公司上调全年指引抱有较高期待。此次指引维持不变，被市场解读为隐含下半年盈利增速放缓的信号，从而引发了盘后的抛售压力。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["DVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138346696","title":"异动解读｜达维塔保健盘后下跌6.14%，Q2业绩超预期但全年指引未上调令市场失望","url":"https://stock-news.laohu8.com/highlight/detail?id=1138346696","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1138346696?lang=zh_cn&edition=full","pubTime":"2026-08-05 04:41","pubTimestamp":1785876062,"startTime":"0","endTime":"0","summary":"8月5日，达维塔保健盘后下跌6.14%，报213.99美元/股，成交额3781.36万美元。消息面上，公司发布Q2财报，调整后每股收益4.02美元，超出市场预期的3.88美元，同比增长36.27%；营收35.54亿美元，高于预期的34.96亿美元。考虑到Q1和Q2连续大幅超预期，市场此前对公司上调全年指引抱有较高期待，指引维持不变被视为隐含下半年盈利增速放缓信号，引发盘后抛压。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150458611","title":"财报前瞻 ｜达维塔保健本季营收预计增4.06%，机构观点偏正面","url":"https://stock-news.laohu8.com/highlight/detail?id=1150458611","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1150458611?lang=zh_cn&edition=full","pubTime":"2026-07-28 10:08","pubTimestamp":1785204539,"startTime":"0","endTime":"0","summary":"达维塔保健将在2026年08月04日美股盘后发布新季财报，市场聚焦透析量变化与利润弹性释放。一致预期显示，本季度达维塔保健营收预计为34.96亿美元，同比增长4.06%；调整后每股收益预计为3.88美元，同比增长38.47%；息税前利润预计为5.77亿美元，同比增长7.43%；公司与市场层面未披露本季度毛利率及净利润或净利率的明确预测，相关指标不予展示。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻 ｜达维塔保健本季营收预计增4.06%，机构观点偏正面","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119172565","title":"达维塔保健新增5亿美元B-2档定期贷款额度 到期日为2031年5月","url":"https://stock-news.laohu8.com/highlight/detail?id=1119172565","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119172565?lang=zh_cn&edition=full","pubTime":"2026-06-09 04:39","pubTimestamp":1780951151,"startTime":"0","endTime":"0","summary":"根据提交给美国证券交易委员会（SEC）的文件，达维塔保健（DaVita HealthCare Partners）为其B-2档定期贷款额度增加了5亿美元的增量借款，该贷款额度的到期日为2031年5月。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4559","DVA","BK4585","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120883918","title":"一周美股牛榜 | Datadog业绩大超预期，股价飙升42%；Akamai股价单周大涨42%；SMCI季度营收指引超预期，股价飙升30%；AMD涨26%；英特尔涨25%","url":"https://stock-news.laohu8.com/highlight/detail?id=1120883918","media":"老虎资讯综合","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120883918?lang=zh_cn&edition=full","pubTime":"2026-05-11 10:31","pubTimestamp":1778466709,"startTime":"0","endTime":"0","summary":"Datadog公布营收达10.06亿美元，同比增长32%；调整后每股收益为0.60美元，双双超越市场预期。这一消息发布之际，Akamai公布一季度每股收益为1.61美元，去年同期为1.70美元，略高于华尔街预期的1.60美元。AMD股价本周大涨26%。受此消息影响，英特尔本周涨幅扩大至25%。","market":"us","thumbnail":"https://community-static.tradeup.com/news/b709e81a1b4f7405bf5e343b3c9425a7","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/b709e81a1b4f7405bf5e343b3c9425a7"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MUU","AMDL","SMYY","SMCZ","DDOG","DELL","SMCX","MU","INTW","MUD","DVA","AMDD","AKAM","DAMD","LINT","SNXX","SNDK","AMDU","INTC","AMD","AMUU","AMYY","SMCY","AMDY","MULL","AMDW","DOGD","DLLL","AMDG","SNDU","SMCC","SMCI","FTNT","SMCL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183596383","title":"异动解读 | 达维塔保健盘中大涨22.55%，一季度业绩超预期并上调全年盈利指引","url":"https://stock-news.laohu8.com/highlight/detail?id=1183596383","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1183596383?lang=zh_cn&edition=full","pubTime":"2026-05-07 03:38","pubTimestamp":1778096282,"startTime":"0","endTime":"0","summary":"达维塔保健今日盘中股价大幅上涨22.55%，成为市场关注的焦点。消息面上，该公司公布了远超市场预期的2026年第一季度财务业绩，并基于肾透析服务需求的强劲与稳定增长，上调了全年调整后利润预期。具体而言，公司第一季度调整后每股收益为2.87美元，大幅高于分析师普遍预期的2.32美元；季度营收达到34.2亿美元，也超出了33.6亿美元的市场预期。同时，公司将2026年全年经调整后每股收益预期区间上调至14.10美元至15.20美元，高于此前13.60美元至15.00美元的指引。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["DVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130324878","title":"异动解读 | 达维塔保健盘前大涨7.10%，业绩超预期并上调全年盈利指引","url":"https://stock-news.laohu8.com/highlight/detail?id=1130324878","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1130324878?lang=zh_cn&edition=full","pubTime":"2026-05-06 16:40","pubTimestamp":1778056845,"startTime":"0","endTime":"0","summary":"达维塔保健（DVA）今日盘前股价大幅上涨7.10%，成为市场关注的焦点。消息面上，该公司公布了超出华尔街预期的第一季度业绩，并基于肾透析服务需求的强劲与稳定增长，上调了全年调整后利润预期。具体而言，公司目前预计2026年经调整后每股收益将在14.10美元至15.20美元之间，高于此前预测的13.60美元至15.00美元。财报数据显示，在截至3月31日的季度，该公司按调整后数据计算的每股盈利为2.87美元，高于分析师预期的2.32美元；季度营收达到34.2亿美元，也高于市场预期的33.6亿美元。这表明公司在应对患者护理和运营成本上涨的挑战后，业务已重拾增长势头，从而提振了投资者信心。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["DVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145550923","title":"异动解读 | 业绩超预期并上调盈利指引，达维塔保健夜盘大涨5.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=1145550923","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1145550923?lang=zh_cn&edition=full","pubTime":"2026-05-06 11:12","pubTimestamp":1778037123,"startTime":"0","endTime":"0","summary":"达维塔保健（DVA）今日夜盘股价大涨5.39%，成为市场关注的焦点。消息面上，公司公布了超出华尔街预期的第一季度业绩，并基于肾透析服务需求的强劲与稳定增长，上调了全年调整后利润预期。具体而言，公司目前预计2026年经调整后每股收益将在14.10美元至15.20美元之间，高于此前预测的13.60美元至15.00美元。财报数据显示，在截至3月31日的季度，该公司按调整后数据计算的每股盈利为2.87美元，高于分析师预期的2.32美元；季度营收达到34.2亿美元，也高于市场预期的33.6亿美元。这表明公司在应对运营成本挑战后，业务已重拾增长势头，从而提振了投资者信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["DVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125490690","title":"异动解读 | 上调年度盈利预期，达维塔保健盘后大涨5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=1125490690","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1125490690?lang=zh_cn&edition=full","pubTime":"2026-05-06 05:51","pubTimestamp":1778017905,"startTime":"0","endTime":"0","summary":"达维塔保健（DVA）今日盘后股价大幅上涨5.07%，成为市场关注的焦点。消息面上，该公司公布了超出华尔街预期的第一季度业绩，并基于肾透析服务需求的强劲与稳定增长，上调了全年调整后利润预期。具体而言，公司目前预计2026年经调整后每股收益将在14.10美元至15.20美元之间，高于此前预测的13.60美元至15.00美元。财报数据显示，在截至3月31日的季度，该公司按调整后数据计算的每股盈利为2.87美元，高于分析师预期的2.32美元；季度营收达到34.2亿美元，也高于市场预期的33.6亿美元。这表明公司在应对患者护理和运营成本上涨的挑战后，业务已重拾增长势头。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["DVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620407373","title":"巴菲特重仓的透析巨头，为何押注中国肾病新星？","url":"https://stock-news.laohu8.com/highlight/detail?id=2620407373","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2620407373?lang=zh_cn&edition=full","pubTime":"2026-03-18 09:08","pubTimestamp":1773796126,"startTime":"0","endTime":"0","summary":"最有希望在美国“上市即放量”\n","market":"sh","thumbnail":"https://img3.gelonghui.com/02490-dd1b506f-18f3-46ab-a410-cfb69aa5569f.jpg?guru_height=853&guru_width=1280&guru_size=117711","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/02490-dd1b506f-18f3-46ab-a410-cfb69aa5569f.jpg?guru_height=853&guru_width=1280&guru_size=117711"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/4100986","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK4534","LU1280957306.USD","LU2487616109.SGD","IE000M9KFDE8.USD","LU0130102774.USD","IE00BJLML261.HKD","LU0234572021.USD","LU2168564222.USD","LU2168564495.EUR","BRKU","BK4585","LU0980610538.SGD","LU2168563687.JPY","LU0157215616.USD","LU0170899867.USD","BRKC","IE00BWXC8680.SGD","LU0648001328.SGD","LU1914381329.SGD","IE0034235303.USD","LU2168564065.EUR","IE00BK4W5L77.USD","LU1074936037.SGD","LU1363072403.SGD","LU1366333091.USD","LU0640476718.USD","LU0154236417.USD","LU0048573561.USD","IE00B1BXHZ80.USD","LU0742534661.SGD","LU0251142724.SGD","IE00B1XK9C88.USD","BK4176","BRKD","BRKW","BK4581","LU0256863811.USD","IE00BK4W5M84.HKD","BK4533","LU1571399168.USD","LU0787776722.HKD","LU0683600562.USD","LU0149725797.USD","BK4550","HK0000914660.USD","IE00BKDWB100.SGD","BK4588","LU0417517546.SGD","LU2168564149.EUR","LU0251131958.USD","LU0234570918.USD","LU0971096721.USD","LU0053666078.USD","LU0210528500.USD","IE00B775SV38.USD","LU1201861249.SGD","HK0000914686.HKD","DVA","IE00B3S45H60.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157539444","title":"R1 Therapeutics完成融资，Abingworth、F-Prime与达维塔风投集团联合领投，Curie.bio、Symbiosis及美国肾脏护理公司跟投","url":"https://stock-news.laohu8.com/highlight/detail?id=1157539444","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157539444?lang=zh_cn&edition=full","pubTime":"2026-03-17 19:00","pubTimestamp":1773745220,"startTime":"0","endTime":"0","summary":"生物技术公司R1 Therapeutics近日宣布成功完成新一轮融资。本轮融资由知名投资机构Abingworth、F-Prime Capital与达维塔风投集团（DaVita Venture Group）共同担任联合领投方。同时获得Curie.bio、Symbiosis以及美国肾脏护理公司（U.S. Renal Care）等多家机构的积极参与。\n此次融资将用于加速R1 Therapeutics在肾脏疾病治疗领域的创新药物研发进程，推动其前沿疗法从实验室向临床阶段转化。多方资本的注入不仅彰显了市场对肾脏病治疗赛道的信心，也为企业后续发展提供了强有力的资金保障。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4196","BK4585","DVA","BK4559"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513084252","title":"巴菲特，又有大动作！","url":"https://stock-news.laohu8.com/highlight/detail?id=2513084252","media":"央视财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513084252?lang=zh_cn&edition=full","pubTime":"2025-02-21 17:13","pubTimestamp":1740129180,"startTime":"0","endTime":"0","summary":"转自：央视财经据路透社报道，近期美国证券交易委员会披露的一份文件显示，美国知名投资人巴菲特旗下伯克希尔-哈撒韦公司在2月14日至19日合计减持美国医疗保健公司达维塔（DaVita）共计75万股，套现约1.15亿美元，约合人民币8.3亿元。此次减持以后，伯克希尔持有达维塔的股份数量降至3514万股，持股比例降至43.93%。据悉，这并非巴菲特第一次减持该股，此前在2月11日也减持了约20万股。从股价表现来看，达维塔近期走势震荡，1月末一度涨至179.60美元/股，但2月14日该股突然暴跌超11%。目前达维塔最新市值为116.7亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221173826abd75f41&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221173826abd75f41&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1074936037.SGD","LU0234572021.USD","IE00B1BXHZ80.USD","LU0157215616.USD","LU0256863811.USD","BK4176","LU0417517546.SGD","LU1201861249.SGD","BRK.B","BK4534","BK4559","BK4585","LU0251131958.USD","BK4196","LU0683600562.USD","BK4581","BK4533","LU0154236417.USD","IE00B3S45H60.SGD","IE00B775SV38.USD","LU0053666078.USD","LU0251142724.SGD","LU0130102774.USD","LU0648001328.SGD","LU0742534661.SGD","LU0234570918.USD","LU0971096721.USD","LU0048573561.USD","BK4550","IE00B1XK9C88.USD","BRK.A","LU0980610538.SGD","IE00BKDWB100.SGD","LU1914381329.SGD","LU1366333091.USD","DVA","IE00BWXC8680.SGD","LU1571399168.USD","LU0640476718.USD","LU1363072403.SGD","LU0149725797.USD","BK4588","IE00BK4W5M84.HKD","IE00BK4W5L77.USD","LU1280957306.USD","IE000M9KFDE8.USD","LU0787776722.HKD","LU0170899867.USD","IE0034235303.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512267829","title":"德维特2024财年实现净利润9.36亿美元，同比增加35.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512267829","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512267829?lang=zh_cn&edition=full","pubTime":"2025-02-18 00:00","pubTimestamp":1739808034,"startTime":"0","endTime":"0","summary":"2月18日，德维特公布财报，公告显示公司2024财年净利润为9.36亿美元，同比增加35.26%；其中营业收入为128.16亿美元，同比增加5.57%，每股基本收益为11.02美元。从资产负债表来看，德维特总负债158.81亿美元，其中短期债务6.81亿美元，资产负债比为1.14，流动比率为1.27。机构评级：截至2025年2月18日，当前有7家机构对德维特目标价做出预测，其中目标均价为167.00美元，其中最低目标价为145.00美元，最高目标价为186.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218000043a2496358&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218000043a2496358&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["DVA"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.davita.com","stockEarnings":[{"period":"1week","weight":-0.0202},{"period":"1month","weight":-0.2226},{"period":"3month","weight":-0.0985},{"period":"6month","weight":0.2089},{"period":"1year","weight":0.3398},{"period":"ytd","weight":0.5849}],"compareEarnings":[{"period":"1week","weight":0.004},{"period":"1month","weight":0.0285},{"period":"3month","weight":0.0503},{"period":"6month","weight":0.1387},{"period":"1year","weight":0.2037},{"period":"ytd","weight":0.1385}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"DaVita Inc.于1994年在特拉华州注册成立。达维塔保健 Inc.是一家领先的医疗保健供应商，专注于转变护理提供方式，以提高全球患者的生活质量。作为一家综合性肾脏护理提供者，达维塔保健拥有超过25年的经验，它提供的服务可在患者肾脏健康之旅的每个阶段为其提供支持——从减缓肾脏疾病的进展到促进移植。该公司经营透析中心，为家庭护理提供支持，并在医院和熟练的护理设施中提供服务。达维塔保健对创新和综合护理的承诺旨在改善结果，同时最大限度地降低成本，从而加强其作为值得信赖的提供者和合作伙伴在医疗保健领域的地位。","yearOnYearQuotes":[{"month":1,"riseRate":0.516129,"avgChangeRate":0.002865},{"month":2,"riseRate":0.483871,"avgChangeRate":-0.007883},{"month":3,"riseRate":0.548387,"avgChangeRate":0.019696},{"month":4,"riseRate":0.645161,"avgChangeRate":0.025606},{"month":5,"riseRate":0.612903,"avgChangeRate":0.026568},{"month":6,"riseRate":0.612903,"avgChangeRate":0.048539},{"month":7,"riseRate":0.548387,"avgChangeRate":-0.005018},{"month":8,"riseRate":0.419355,"avgChangeRate":-0.01376},{"month":9,"riseRate":0.566667,"avgChangeRate":0.017103},{"month":10,"riseRate":0.5,"avgChangeRate":0.001552},{"month":11,"riseRate":0.612903,"avgChangeRate":0.050929},{"month":12,"riseRate":0.580645,"avgChangeRate":0.040515}],"exchange":"NYSE","name":"达维塔保健","nameEN":"DaVita HealthCare Partners"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"达维塔保健(DVA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供达维塔保健(DVA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"达维塔保健,DVA,达维塔保健股票,达维塔保健股票老虎,达维塔保健股票老虎国际,达维塔保健行情,达维塔保健股票行情,达维塔保健股价,达维塔保健股市,达维塔保健股票价格,达维塔保健股票交易,达维塔保健股票购买,达维塔保健股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"达维塔保健(DVA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供达维塔保健(DVA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}